Biblio Discovery — Demo Discovery Service

3 hasil untuk "Timothy Schieber"

Menampilkan 1–3 · 0,41 detik · RSS

  1. Artikel Jurnal

    Complete Response to Pembrolizumab in Prostate Cancer With Microsatellite Instability–High, Deficient Mismatch Repair, Tumor Mutational Burden–High, and Programmed Death–Ligand 1 Positivity

    Tobin Wise; Jennifer Heins; Timothy Schieber dkk.

    Annals of Internal Medicine: Clinical Cases, Vol. 5 No. 3 · 2026 · Inggris · DOAJ Scopus

    A 72-year-old man initially presented with prostate cancer and a metastatic right rib lesion. He developed rapid progression on androgen deprivation therapy in 7 months and subsequent treatment with enzalutamide in 3 months. Biomarker studies after progression to castration-resistant prostate…

  2. Artikel Jurnal

    Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis

    Timothy Schieber; Kelly Brunk; Anna Clennon dkk.

    Experimental Hematology & Oncology, Vol. 14 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Penile squamous cell carcinoma (PSCC) is a rare malignancy, and first-line therapy typically involves cisplatin-based chemotherapy. However, these regimens are often unsuitable for patients with poor performance status or advanced age due to their toxicity. This retrospective, multicenter…

  3. Artikel Jurnal

    Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma

    Sanjana Mullangi, MD; Manidhar Reddy Lekkala, MD; Sarah Blocker, PharmD dkk.

    JTO Clinical and Research Reports, Vol. 6 No. 11 · 2025 · Inggris · DOAJ Scopus

    Introduction: SCLC remains the most aggressive lung cancer with a poor prognosis. Tarlatamab, a bispecific T-cell engager, is approved for use in extensive-stage SCLC after progression on a platinum-based chemotherapy on the basis of the DeLLphi-301 trial. Because of the restrictive inclusion…